Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc.
- Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that can infect humans.
- Kermode will fund for one year the discovery of product candidates for the African Swine Fever Virus (ASFV), with an option for swine influenza virus.
- It will retain the exclusive rights to mAbs and vaccines for veterinary uses discovered in the collaboration.
- Aridis will grant a non-exclusive license to the APEX platform and apply it to discover vaccines and mAbs to ASFV.
- Aridis will have the rights for any products for human uses discovered in the collaboration.
- APEX platform is a monoclonal antibody pathogen discovery platform developed by Aridis.
- Price Action: ARDS shares closed 3.4% lower at $5.43 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in